Severe asthma drug may boost daily steps, study hopes
NCT ID NCT05404763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see if better lung function from the drug leads to a more active life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mepolizumab
- What this could lead to
- If successful, this could show that mepolizumab helps severe asthma patients become more physically active, potentially improving their overall health.
- What could go wrong
- This is a small, early-stage study with only 62 participants, so results may not apply to everyone. It focuses on activity levels, not on curing asthma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lille University Hospital
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?